Last reviewed · How we verify
NS (0.9%)
Normal saline (0.9% sodium chloride solution) provides isotonic fluid replacement and maintains electrolyte balance.
Normal saline (0.9% sodium chloride solution) provides isotonic fluid replacement and maintains electrolyte balance. Used for Fluid resuscitation and volume replacement, Electrolyte and hydration maintenance, Vehicle for intravenous drug administration.
At a glance
| Generic name | NS (0.9%) |
|---|---|
| Also known as | Normal saline solution 0.9%, Physiologic saline solution |
| Sponsor | Ministry of Health, Spain |
| Drug class | Crystalloid fluid / Electrolyte solution |
| Modality | Small molecule |
| Therapeutic area | Supportive Care / Fluid Management |
| Phase | Phase 3 |
Mechanism of action
NS is a crystalloid solution containing 0.9% sodium chloride in water, formulated to match the osmolarity of blood plasma. It is used for intravenous fluid resuscitation, electrolyte replacement, and as a vehicle for drug administration. It has no active pharmacological mechanism but serves as a physiological support agent.
Approved indications
- Fluid resuscitation and volume replacement
- Electrolyte and hydration maintenance
- Vehicle for intravenous drug administration
Common side effects
- Hyperchloremic acidosis (with large volumes)
- Fluid overload / pulmonary edema (in susceptible patients)
- Hyponatremia (rare, with excessive hypotonic administration)
Key clinical trials
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT (PHASE2)
- Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis (PHASE3)
- Perioperative Multimodal Analgesia Protocol for Supratentorial Craniotomy (NA)
- Aerosolized Endotracheal Lidocaine to Avoid Intracranial Pressure Spikes in Patients With Severe Traumatic Brain Injury (PHASE4)
- Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine (PHASE1)
- MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI (PHASE2)
- Diltiazem in the Treatment of Atrial Fibrillation or Atrial Flutter With Rapid Ventricular Rate (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NS (0.9%) CI brief — competitive landscape report
- NS (0.9%) updates RSS · CI watch RSS
- Ministry of Health, Spain portfolio CI